Insider · CIK 0001832694
Spyros Papapetropoulos
Files at NEUP (Neuphoria Therapeutics Inc.), LPCN (Lipocine Inc.). First filing -, latest -.
In brief
Spyros Papapetropoulos files SEC Form 4 as director, CEO and president at NEUP (Neuphoria Therapeutics Inc.), and also at LPCN (Lipocine Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Spyros Papapetropoulos has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 27, 2025 | NEUP Neuphoria Therapeutics Inc. | AGrant or award Employee Stock Option (Right-to- Buy)derivative | +34,559 | $8.27 | $286k | 74,088 | Sep 2, 2025 |
| Jun 4, 2025 | LPCN Lipocine Inc. | AGrant or award Stock Option (Right to Buy)derivative | +1,764 | $3.20 | $5,645 | 7,174 | Jun 5, 2025 |
| Apr 16, 2025 | NEUP Neuphoria Therapeutics Inc. | AGrant or award Employee Stock Option (Right-to-Buy)derivative | +27,000 | $5.16 | $139k | 39,529 | May 19, 2025 |
| Apr 16, 2025 | NEUP Neuphoria Therapeutics Inc. | AGrant or award Employee Stock Option (Right-to-Buy)derivative | +270,000 | $5.16 | $1.4M | 282,529 | Apr 18, 2025 |
Questions about Spyros Papapetropoulos
Answered from the filings on this page, as of the latest one.
Is Spyros Papapetropoulos buying or selling?
Spyros Papapetropoulos has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Spyros Papapetropoulos's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Spyros Papapetropoulos has 0.
Where does Spyros Papapetropoulos file Form 4?
Spyros Papapetropoulos has filed Form 4 at NEUP (Neuphoria Therapeutics Inc.) as President and CEO; LPCN (Lipocine Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.